<![CDATA[Calliditas Therapeutics: FDA approval of TARPEYO®]]>Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Link Preview Image
Calliditas Therapeutics AB

Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

favicon

Calliditas Therapeutics AB (www.calliditas.se)

]]>https://dev.proinvestor.com/forum/topic/445939/calliditas-therapeutics-fda-approval-of-tarpeyoRSS for NodeSun, 21 Jun 2026 14:19:16 GMTWed, 20 Dec 2023 20:25:16 GMT60<![CDATA[Reply to Calliditas Therapeutics: FDA approval of TARPEYO® on Wed, 27 Dec 2023 09:26:55 GMT]]>Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patien

Link Preview Image
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and...

favicon

(www.prnewswire.com)

"SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration (TFDA) for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon® was the first ever treatment for IgAN approved in U.S., European Union and mainland China. Everest expects approval of Nefecon® in Taiwan in 2024."

]]>https://dev.proinvestor.com/forum/post/9486324https://dev.proinvestor.com/forum/post/9486324Wed, 27 Dec 2023 09:26:55 GMT<![CDATA[Reply to Calliditas Therapeutics: FDA approval of TARPEYO® on Fri, 22 Dec 2023 05:55:16 GMT]]>Calliditas: Interview with CEO Renée Aguiar-Lucander

"Redeye interviews Callidias CEO Renée Aguiar-Lucander, after securing a full FDA approval for Tarpeyo."

Just a moment...

favicon

(www.redeye.se)

]]>https://dev.proinvestor.com/forum/post/9486326https://dev.proinvestor.com/forum/post/9486326Fri, 22 Dec 2023 05:55:16 GMT